Back to Search Start Over

Impact of Preoperative Diagnostic Biopsy Procedure on Spread Through Airspaces and Related Outcomes in Resected Stage I Non-Small Cell Lung Cancer.

Authors :
Lee, Ga Young
Chung, Jin-Haeng
Cho, Sukki
Han, Yeon Bi
Park, Young Mi
Kim, Hyung-Jun
Song, Myung Jin
Kwon, Byoung Soo
Lim, Sung Yoon
Lee, Yeon Joo
Park, Jong Sun
Cho, Young-Jae
Yoon, Ho Il
Lee, Jae Ho
Lee, Choon-Taek
Kim, Yeon Wook
Source :
CHEST. Nov2022, Vol. 162 Issue 5, p1199-1212. 14p.
Publication Year :
2022

Abstract

<bold>Background: </bold>Tumor spread through airspaces (STAS) is a recently determined pathologic phenomenon of lung cancer with significant prognostic impact. This study aimed to analyze the unexplored correlation between preoperative biopsy procedure and a higher risk of STAS and its impact on STAS-related outcomes in resected stage I non-small cell lung cancer (NSCLC).<bold>Research Question: </bold>Does preoperative biopsy procedure affect the risk of STAS and STAS-related outcomes in surgically treated stage I NSCLC?<bold>Study Design and Methods: </bold>We examined 2,169 patients who underwent surgery for pathologic stage I NSCLC from January 2011 through December 2019 at the Seoul National University Bundang Hospital, a tertiary center in South Korea. Factors including percutaneous needle biopsy (PCNB) and bronchoscopic biopsy were assessed for determining the association between preoperative biopsy procedure and an elevated risk of STAS. In addition, the impact of preoperative biopsy on STAS-related prognosis (recurrence and lung cancer-specific mortality) was evaluated with multivariate Cox regression analyses.<bold>Results: </bold>STAS findings were positive in 638 of 2,169 patients (29.4%). An insignificant association was found between preoperative biopsy (both PCNB and bronchoscopic biopsy) and STAS. After adjustments for preoperative tumor biopsy, STAS was a significant risk factor for cancer recurrence (hazard ratio [HR], 1.72; 95% CI, 1.20-2.48). Additionally, sublobar resection remained a significant risk factor for recurrence (HR, 3.20; 95% CI, 1.65-6.21) and lung cancer-specific mortality (HR, 12.71; 95% CI, 3.68-43.92) in patients with positive STAS findings. However, this association was insignificant for patients without STAS. Preoperative biopsy was not a significant risk factor for either recurrence and mortality, regardless of STAS positivity.<bold>Interpretation: </bold>Preoperative biopsy in stage I NSCLC neither was associated with an elevated risk of STAS nor influenced the prognosis related to STAS. Physicians can be less apprehensive about performing preoperative biopsy in relationship to STAS. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00123692
Volume :
162
Issue :
5
Database :
Academic Search Index
Journal :
CHEST
Publication Type :
Academic Journal
Accession number :
159930574
Full Text :
https://doi.org/10.1016/j.chest.2022.05.002